The pace of initial public offerings by Massachusetts biotechnology companies continues to pick up momentum, as a pair of Cambridge companies that previously filed to go public priced their shares this week.
Acceleron Pharma Inc., which is developing protein-based drugs to treat rare blood disorders, said Friday it will seek to raise about $65 million by offering 4.7 million shares to public investors at a price range of between $13 and $15 a share.
On Thursday, Bind Therapeutics Inc., which is developing programmable drugs to treat lung cancer and prostate cancer, indicated it plans to raise $71 million by selling 4.7 million shares at a range of $14 to $16.
Once they begin trading, Acceleron would be listed as XLRN and Bind as BIND on the Nasdaq stock exchange.
The companies would join five other Massachusetts biotechs that have completed IPOs this year: Enanta Pharmaceuticals Inc. and Tetraphase Pharmaceuticals Inc. of Watertown and Cambridge-based Epizyme Inc., Bluebird Bio Inc., and Agio Pharmaceuticals Inc. Another biotechnology company, Foundation Medicine Inc. of Cambridge registered for an IPO at the end of July.